Last reviewed · How we verify
NCT07393594: ID-ENTITY
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
trial testing Blood tests, TRAC( cell free DNA) and T-ID in Kidney Diseases in 1,000 participants. Not yet recruiting.
30 April 2028
Quick facts
| Lead sponsor | Transplant Genomics, Inc. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 31 March 2026 |
| Primary completion | 30 April 2028 |
| Estimated completion | 30 October 2028 |
Drugs / interventions tested
- Blood tests, TRAC( cell free DNA) and T-ID
Conditions studied
- Kidney Diseases — all drugs for Kidney Diseases →
- Kidney Injury — all drugs for Kidney Injury →
- BK Virus Infection — all drugs for BK Virus Infection →
- CMV — all drugs for CMV →
Sponsor
Transplant Genomics, Inc. — full company profile →
Who can join
18 and older, any sex, with Kidney Diseases or Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney transplantation, accounting for the net immune environment (TTV viral load) and allograft injury (donor-derived cell-free DNA, dd-cfDNA).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07393594
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Diseases
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
- NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
- NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
- NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting
Other Transplant Genomics, Inc. trials
Trials by the same sponsor.
- NCT07231328 — PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients) · not yet recruiting
- NCT05335538 — TruGraf and TRAC In Pediatrics Study · unknown
- NCT04670926 — Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test · NA · unknown
- NCT04267016 — Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care · terminated
- NCT04398498 — Molecular Biomarkers in Renal Transplantation Via TruGraf® Test · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07393594 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Transplant Genomics, Inc.
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07393594.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing